Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Transplant Cell Ther. 2021 Dec 4;28(2):73.e1–73.e9. doi: 10.1016/j.jtct.2021.11.019

Table 2:

Treatment Characteristics (n = 31)

Lymphodepletion* (number [%])
 Flu (120 mg/m2)/Cy (1000 mg/m2) 19 (61.3)
 Flu (75 mg/m2)/Cy (900 mg/m2) 10 (32.3)
 Flu (75 mg/m2)/Cy (900 mg/m2)/Eto (500 mg/m2) 1 (3.2)
 Flu (75 mg/m2)/Cy (900 mg/m2)/Ara-C (4 g/m2) 1 (3.2)
CAR T-cell dose administered (median [range])
 Patients ≤ 50 kg (n = 21) 2.1 [0.9–4.5] **
 Patients > 50 kg (n = 10) 1.1 [0.5–1.6] ***

Flu: fludarabine; Cy: cyclophosphamide; Eto: etoposide; Ara-C: cytarabine

*

cumulative doses

**

×106 CAR-positive T cells/kg patient weight

***

×108 CAR-positive T cells.